7096 Background: Mogamulizumab, monoclonal antibody against CCR4, is approved for relapsed/refractory cutaneous T cell lymphoma (CTCL), with an overall response rate of 28%in CTCL. The most common toxicity is mogamulizumab-associated rash (MAR), occurring in ~24% of patients and reported in up to 88% of responders, frequently leading to treatment discontinuation. Given the limited therapeutic options in CTCL, retreatment with mogamulizumab is clinically appealing but not well described. We repor